#### INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 11, 19-23 because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 11 and 19-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.:  because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
(
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

# DEC 0 2 1005 98-2"

#### PATENT COOPERATION TREATY

### **PCT**

#### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	
	· ·	see Form PCT/ISA/220 well as, where applicable, item 5 below.
3275-3 PCT-1 International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
••		
PCT/EP2004/005996	03/06/2004	04/06/2003
Applicant		·
GESELLSCHAFT FUR BIOTECHNO	OTOGTECUE FORSCHING MRH	
GESDELISCHAFT FOR DICTACHA	THOSE LOWSCHOIL HILL	
This International Search Report has bee according to Article 18. A copy is being to	n prepared by this International Searching ansmitted to the International Bureau.	Authority and is transmitted to the applicant
This international Search Report consists	of a total of <u>5</u> sheets.	
X It is also accompanied by	a copy of each prior art document cited in	this report.
<ol> <li>Basis of the report</li> <li>With regard to the language, the language in which it was filed, un</li> </ol>	international search was carried out on the less otherwise indicated under this item.	basis of the international application in the
The international this Authority (Ru		anslation of the international application furnished to
b. With regard to any nucle	otide and/or amino acid sequence disclo	sed in the international application, see Box No. i.
2. Certain claims were fou	and unsearchable (See Box II).	•
3. Unity of invention is lac	king (see Box III).	
4. With regard to the title,		
<b>=</b>	ubmitted by the applicant.	
	shed by this Authority to read as follows:	
THERAPEUTICAL COMPOS	ITION CONTAINING DENTRITIC	C CELLS AND USE THEREOF
5. With regard to the abstract,		
	ubmitted by the applicant.	
the text has been establis	shed, according to Rule 38.2(b), by this Aut	hority as it appears in Box No. IV. The applicant
may, within one month fro	om the date of mailing of this international s	search report, submit comments to this Authority.
6. With regards to the <b>drawings,</b>		
	published with the abstract is Figure No	
as suggested by	the applicant.	
as selected by th	is Authority, because the applicant failed to	suggest a figure.
´	is Authority, because this figure better char	acterizes the invention.
b. X none of the figures is to b	pe published with the abstract.	

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K35/14 A61K35/26

A61P35/00 A61P33/00

A61K35/66 A61P37/00

A61K38/21

A61P31/00

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCHULER G ET AL: "The use of dendritic cells in cancer immunotherapy" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD. LONDON, GB, vol. 15, no. 2, April 2003 (2003-04), pages 138-147, XP004414291 ISSN: 0952-7915 page 139 - page 140 page 143, column 2	1-23

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents:      A* document defining the general state of the art which is not considered to be of particular relevance      E* earlier document but published on or after the international filling date      L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another cliation or other special reason (as specified)      O* document referring to an oral disclosure, use, exhibition or other means      P* document published prior to the international filing date but later than the priority date claimed	<ul> <li>"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>
Date of the actual completion of the international search	Date of mailing of the international search report
16 September 2004	30/09/2004

16 September 2004

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

**Authorized officer** 

Markopoulos, E

## PCT/EP2004/005996

		PC1/EF2004/005330
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, or the relevant passages	
Y	BOONSTRA ANDRE ET AL: "Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential Toll-like receptor ligation."  JOURNAL OF EXPERIMENTAL MEDICINE, vol. 197, no. 1, 6 January 2003 (2003-01-06), pages 101-109, XP002256542 ISSN: 0022-1007 cited in the application page 101 - page 102	1-23
Y	FR 2 796 961 A (CT HOSPITALIER UNIVERSITAIRE D) 2 February 2001 (2001-02-02) claims 1-9; example 7	1-23
Υ	EP 1 291 414 A (GENETHOR GMBH) 12 March 2003 (2003-03-12) claims 1-28	1-23
Y	SCHILLING, DAGMAR ET AL: "Toll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein ( TIRAP )/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages" JOURNAL OF IMMUNOLOGY , 169(10), 5874-5880 CODEN: JOIMA3; ISSN: 0022-1767, 2002, XP002296565 page 5876, column 1 - column 2, paragraph 2 page 5875, column 1, paragraph 4 abstract	16-18
P,Y	EP 1 382 352 A (BIOTECHNOLOG FORSCHUNG GMBH) 21 January 2004 (2004-01-21) page 5, line 6 - line 39; claims 5-9	16-20, 22,23

#### Information on patent family members

PCT/EP2004/005996

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
FR 2796961	A	02-02-2001	FR AU EP WO	2796961 A1 7009600 A 1198558 A1 0109288 A1	02-02-2001 19-02-2001 24-04-2002 08-02-2001
EP 1291414	Α	12-03-2003	EP WO	1291414 A1 03012080 A2	12-03-2003 13-02-2003
EP 1382352	A	21-01-2004	EP WO	1382352 A1 2004009125 A2	21-01-2004 29-01-2004